Abstract
We have recently developed a non-cytopathic RNA replicon-based viral vector system based on the flavivirus Kunjin. Here, we illustrate the utility of the Kunjin replicon system for gene therapy. Intra-tumoral injections of Kunjin replicon virus-like particles encoding granulocyte colony-stimulating factor were able to cure >50% of established subcutaneous CT26 colon carcinoma and B16-OVA melanomas. Regression of CT26 tumours correlated with the induction of anti-cancer CD8 T cells, and treatment of subcutaneous CT26 tumours also resulted in the regression of CT26 lung metastases. Only a few immune-based strategies are able to cure these aggressive tumours once they are of a reasonable size, illustrating the potential of this vector system for intra-tumoral gene therapy applications.
Similar content being viewed by others
References
Gupta P, Su ZZ, Lebedeva IV, Sarkar D, Sauane M, Emdad L et al. mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacol Ther 2006; 111: 596–628.
Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006; 12: 6737–6747.
Peng Z . Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 2005; 16: 1016–1027.
Favaro E, Indraccolo S . Gene therapy of cancer in the clinic: good news in sight from Asia? Curr Opin Mol Ther 2007; 9: 477–482.
Pijlman GP, Suhrbier A, Khromykh AA . Kunjin virus replicons: an RNA-based, non-cytopathic viral vector system for protein production, vaccine and gene therapy applications. Expert Opin Biol Ther 2006; 6: 135–145.
Khromykh AA . Replicon-based vectors of positive strand RNA viruses. Curr Opin Mol Ther 2000; 2: 555–569.
Yamanaka R . Alphavirus vectors for cancer gene therapy (Review). Int J Oncol 2004; 24: 919–923.
Harvey TJ, Liu WJ, Wang XJ, Linedale R, Jacobs M, Davidson A et al. Tetracycline-inducible packaging cell line for production of flavivirus replicon particles. J Virol 2004; 78: 531–538.
Hall RA, Broom AK, Smith DW, Mackenzie JS . The ecology and epidemiology of Kunjin virus. Curr Top Microbiol Immunol 2002; 267: 253–269.
Pugachev KV, Guirakhoo F, Ocran SW, Mitchell F, Parsons M, Penal C et al. High fidelity of yellow fever virus RNA polymerase. J Virol 2004; 78: 1032–1038.
Ketola A, Schlesinger S, Wahlfors J . Properties of Sindbis virus vectors produced with a chimeric split helper system. Int J Mol Med 2005; 15: 999–1003.
Varnavski AN, Young PR, Khromykh AA . Stable high-level expression of heterologous genes in vitro and in vivo by noncytopathic DNA-based Kunjin virus replicon vectors. J Virol 2000; 74: 4394–4403.
Hege KM, Jooss K, Pardoll D . GM-CSF gene-modified cancer cell immunotherapies: of mice and men. Int Rev Immunol 2006; 25: 321–352.
Crittenden MR, Thanarajasingam U, Vile RG, Gough MJ . Intratumoral immunotherapy: using the tumour against itself. Immunology 2005; 114: 11–22.
Wu Q, Mahendran R, Esuvaranathan K . Nonviral cytokine gene therapy on an orthotopic bladder cancer model. Clin Cancer Res 2003; 9: 4522–4528.
Heller L, Pottinger C, Jaroszeski MJ, Gilbert R, Heller R . In vivo electroporation of plasmids encoding GM-CSF or interleukin-2 into existing B16 melanomas combined with electrochemotherapy induces long-term antitumour immunity. Melanoma Res 2000; 10: 577–583.
Ju DW, Cao X, Acres B . Intratumoral injection of GM-CSF gene encoded recombinant vaccinia virus elicits potent antitumor response in a mixture melanoma model. Cancer Gene Ther 1997; 4: 139–144.
Hill HC, Conway Jr TF, Sabel MS, Jong YS, Mathiowitz E, Bankert RB et al. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res 2002; 62: 7254–7263.
Hubert P, Evrard B, Maillard C, Franzen-Detrooz E, Delattre L, Foidart JM et al. Delivery of granulocyte-macrophage colony-stimulating factor in bioadhesive hydrogel stimulates migration of dendritic cells in models of human papillomavirus-associated (pre)neoplastic epithelial lesions. Antimicrob Agents Chemother 2004; 48: 4342–4348.
Ali S, Ahmad M, Lynam J, Rees RC, Brown N . Trafficking of tumor peptide-specific cytotoxic T lymphocytes into the tumor microcirculation. Int J Cancer 2004; 110: 239–244.
Pan PY, Li Y, Li Q, Gu P, Martinet O, Thung S et al. In situ recruitment of antigen-presenting cells by intratumoral GM-CSF gene delivery. Cancer Immunol Immunother 2004; 53: 17–25.
Li Q, Pan PY, Gu P, Xu D, Chen SH . Role of immature myeloid Gr-1+ cells in the development of antitumor immunity. Cancer Res 2004; 64: 1130–1139.
Zeh III HJ, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC . High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999; 162: 989–994.
Prell RA, Li B, Lin JM, VanRoey M, Jooss K . Administration of IFN-alpha enhances the efficacy of a granulocyte macrophage colony stimulating factor-secreting tumor cell vaccine. Cancer Res 2005; 65: 2449–2456.
Ali SA, Lynam J, McLean CS, Entwisle C, Loudon P, Rojas JM et al. Tumor regression induced by intratumor therapy with a disabled infectious single cycle (DISC) herpes simplex virus (HSV) vector, DISC/HSV/murine granulocyte-macrophage colony-stimulating factor, correlates with antigen-specific adaptive immunity. J Immunol 2002; 168: 3512–3519.
Tagliaferri P, Caraglia M, Budillon A, Marra M, Vitale G, Viscomi C et al. New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer. Cancer Immunol Immunother 2005; 54: 1–10.
Moschella F, Bisikirska B, Maffei A, Papadopoulos KP, Skerrett D, Liu Z et al. Gene expression profiling and functional activity of human dendritic cells induced with IFN-alpha-2b: implications for cancer immunotherapy. Clin Cancer Res 2003; 9: 2022–2031.
Carbonneil C, Aouba A, Burgard M, Cardinaud S, Rouzioux C, Langlade-Demoyen P et al. Dendritic cells generated in the presence of granulocyte-macrophage colony-stimulating factor and IFN-alpha are potent inducers of HIV-specific CD8T cells. AIDS 2003; 17: 1731–1740.
Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML et al. Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 2004; 64: 5934–5937.
Marrack P, Kappler J, Mitchell T . Type I interferons keep activated T cells alive. J Exp Med 1999; 189: 521–530.
Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF . Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 2005; 174: 4465–4469.
Thompson LJ, Kolumam GA, Thomas S, Murali-Krishna K . Innate inflammatory signals induced by various pathogens differentially dictate the IFN-I dependence of CD8 T cells for clonal expansion and memory formation. J Immunol 2006; 177: 1746–1754.
Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K . Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 2005; 202: 637–650.
Zhang X, Yang Z, Dong L, Papageorgiou A, McConkey DJ, Benedict WF . Adenoviral-mediated interferon alpha overcomes resistance to the interferon protein in various cancer types and has marked bystander effects. Cancer Gene Ther 2007; 14: 241–250.
Tsugawa T, Kuwashima N, Sato H, Fellows-Mayle WK, Dusak JE, Okada K et al. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response. Gene Therapy 2004; 11: 1551–1558.
Mazouz N, Detournay O, Buelens C, Renneson J, Trakatelli M, Lambermont M et al. Immunostimulatory properties of human dendritic cells generated using IFN-beta associated either with IL-3 or GM-CSF. Cancer Immunol Immunother 2005; 54: 1010–1017.
Svane IM, Nikolajsen K, Walter MR, Buus S, Gad M, Claesson MH et al. Characterization of monocyte-derived dendritic cells maturated with IFN-alpha. Scand J Immunol 2006; 63: 217–222.
Liu WJ, Chen HB, Wang XJ, Huang H, Khromykh AA . Analysis of adaptive mutations in Kunjin virus replicon RNA reveals a novel role for the flavivirus nonstructural protein NS2A in inhibition of beta interferon promoter-driven transcription. J Virol 2004; 78: 12225–12235.
Liu WJ, Wang XJ, Clark DC, Lobigs M, Hall RA, Khromykh AA . A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice. J Virol 2006; 80: 2396–2404.
Li B, Lalani AS, Harding TC, Luan B, Koprivnikar K, Huan Tu G et al. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res 2006; 12: 6808–6816.
Bollati-Fogolin M, Forno G, Nimtz M, Conradt HS, Etcheverrigaray M, Kratje R . Temperature reduction in cultures of hGM-CSF-expressing CHO cells: effect on productivity and product quality. Biotechnol Prog 2005; 21: 17–21.
Loudon PT, McLean CS, Martin G, Curry J, Leigh Shaw M, Hoogstraten C et al. Preclinical evaluation of DISC-GMCSF for the treatment of breast carcinoma. J Gene Med 2003; 5: 407–416.
Ishii S, Hiroishi K, Eguchi J, Hiraide A, Imawari M . Dendritic cell therapy with interferon-alpha synergistically suppresses outgrowth of established tumors in a murine colorectal cancer model. Gene Therapy 2006; 13: 78–87.
Liu WJ, Wang XJ, Mokhonov VV, Shi PY, Randall R, Khromykh AA . Inhibition of interferon signaling by the New York 99 strain and Kunjin subtype of West Nile virus involves blockage of STAT1 and STAT2 activation by nonstructural proteins. J Virol 2005; 79: 1934–1942.
Anraku I, Mokhonov VV, Rattanasena P, Mokhonova EI, Leung J, Pijlman G et al. Kunjin replicon-based simian immunodeficiency virus gag vaccines. Vaccine 2008; 26: 3268–3276.
Fayzulin R, Scholle F, Petrakova O, Frolov I, Mason PW . Evaluation of replicative capacity and genetic stability of West Nile virus replicons using highly efficient packaging cell lines. Virology 2006; 351: 196–209.
Kriajevska MV, Zakharova LG, Altstein AD . Genetic instability of vaccinia virus containing artificially duplicated genome regions. Virus Res 1994; 31: 123–137.
Junker U, Bohnlein E, Veres G . Genetic instability of a MoMLV-based antisense double-copy retroviral vector designed for HIV-1 gene therapy. Gene Therapy 1995; 2: 639–646.
Lee SG, Kim DY, Hyun BH, Bae YS . Novel design architecture for genetic stability of recombinant poliovirus: the manipulation of G/C contents and their distribution patterns increases the genetic stability of inserts in a poliovirus-based RPS-Vax vector system. J Virol 2002; 76: 1649–1662.
Dufresne AT, Dobrikova EY, Schmidt S, Gromeier M . Genetically stable picornavirus expression vectors with recombinant internal ribosomal entry sites. J Virol 2002; 76: 8966–8972.
Raju R, Subramaniam SV, Hajjou M . Genesis of Sindbis virus by in vivo recombination of nonreplicative RNA precursors. J Virol 1995; 69: 7391–7401.
He Y, Zhang J, Mi Z, Robbins P, Falo Jr LD . Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol 2005; 174: 3808–3817.
Yu P, Lee Y, Liu W, Chin RK, Wang J, Wang Y et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 2004; 5: 141–149.
McAllister A, Arbetman AE, Mandl S, Pena-Rossi C, Andino R . Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases. J Virol 2000; 74: 9197–9205.
Gardner JP, Frolov I, Perri S, Ji Y, MacKichan ML, zur Megede J et al. Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein. J Virol 2000; 74: 11849–11857.
Scheel B, Braedel S, Probst J, Carralot JP, Wagner H, Schild H et al. Immunostimulating capacities of stabilized RNA molecules. Eur J Immunol 2004; 34: 537–547.
Dietrich A, Becherer L, Brinckmann U, Hauss J, Liebert UG, Gutz A et al. Particle-mediated cytokine gene therapy leads to antitumor and antimetastatic effects in mouse carcinoma models. Cancer Biother Radiopharm 2006; 21: 333–341.
McCray AN, Ugen KE, Muthumani K, Kim JJ, Weiner DB, Heller R . Complete regression of established subcutaneous B16 murine melanoma tumors after delivery of an HIV-1 Vpr-expressing plasmid by in vivo electroporation. Mol Ther 2006; 14: 647–655.
Shanker A, Sayers T . Sensitizing tumor cells to immune-mediated cytotoxicity. Adv Exp Med Biol 2007; 601: 163–171.
Breckpot K, Corthals J, Bonehill A, Michiels A, Tuyaerts S, Aerts C et al. Dendritic cells differentiated in the presence of IFN-{beta} and IL-3 are potent inducers of an antigen-specific CD8+ T cell response. J Leukoc Biol 2005; 78: 898–908.
Sarkar D, Lebedeva IV, Gupta P, Emdad L, Sauane M, Dent P et al. Melanoma differentiation associated gene-7 (mda-7)/IL-24: a ‘magic bullet’ for cancer therapy? Expert Opin Biol Ther 2007; 7: 577–586.
Varnavski AN, Khromykh AA . Noncytopathic flavivirus replicon RNA-based system for expression and delivery of heterologous genes. Virology 1999; 255: 366–375.
Anraku I, Harvey TJ, Linedale R, Gardner J, Harrich D, Suhrbier A et al. Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity. J Virol 2002; 76: 3791–3799.
Westaway EG, Mackenzie JM, Kenney MT, Jones MK, Khromykh AA . Ultrastructure of Kunjin virus-infected cells: colocalization of NS1 and NS3 with double-stranded RNA, and of NS2B with NS3, in virus-induced membrane structures. J Virol 1997; 71: 6650–6661.
Macdonald J, Tonry J, Hall RA, Williams B, Palacios G, Ashok MS et al. NS1 protein secretion during the acute phase of West Nile virus infection. J Virol 2005; 79: 13924–13933.
Naparstek E, Pierce J, Metcalf D, Shadduck R, Ihle J, Leder A et al. Induction of growth alterations in factor-dependent hematopoietic progenitor cell lines by cocultivation with irradiated bone marrow stromal cell lines. Blood 1986; 67: 1395–1403.
Antalis TM, La Linn M, Donnan K, Mateo L, Gardner J, Dickinson JL et al. The serine proteinase inhibitor (serpin) plasminogen activation inhibitor type 2 protects against viral cytopathic effects by constitutive interferon alpha/beta priming. J Exp Med 1998; 187: 1799–1811.
Le TT, Drane D, Malliaros J, Cox JC, Rothel L, Pearse M et al. Cytotoxic T cell polyepitope vaccines delivered by ISCOMs. Vaccine 2001; 19: 4669–4675.
Arase N, Arase H, Hirano S, Yokosuka T, Sakurai D, Saito T . IgE-mediated activation of NK cells through Fc gamma RIII. J Immunol 2003; 170: 3054–3058.
Mogal A, Abdulkadir SA . Effects of histone deacetylase inhibitor (HDACi); trichostatin-A (TSA) on the expression of housekeeping genes. Mol Cell Probes 2006; 20: 81–86.
Acknowledgements
This work was funded by a Development Grant from the NH&MRC Australia, and a Commercial Ready Grant from AusIndustry, Australia. Diem Hoang-Le, Leonie Smeenk, and Itaru Anraku should be considered joint first authors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hoang-Le, D., Smeenk, L., Anraku, I. et al. A Kunjin replicon vector encoding granulocyte macrophage colony-stimulating factor for intra-tumoral gene therapy. Gene Ther 16, 190–199 (2009). https://doi.org/10.1038/gt.2008.169
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gt.2008.169
- Springer Nature Limited
Keywords
This article is cited by
-
Viral and Synthetic RNA Vector Technologies and Applications
Molecular Therapy (2016)